Delving into the Latest Updates on MDL-63604 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Mechanism

Protein synthesis inhibitors

Therapeutic Areas

Infectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Bacterial InfectionsCandidiasis, VulvovaginalProtozoan Infections

Originator Organization

Biosearch Italia SpA

Active Organization-

Inactive Organization

Biosearch Italia SpA

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Purpuromycin and its semi-synthetic derivative MDL 63,604 had in-vitro activity similar to that of amphotericin B against isolates of Candida albicans. MDL 63,604 had activity similar to that of metronidazole against Trichomonas vaginalis. Both compounds were very active against most species of Gram-positive and Gram-negative anaerobes and against Gardnerella vaginalis. MDL 63,604 had significantly lower MICs than purpuromycin against T. vaginalis and most of the bacteria, probably due to antagonism of purpuromycin's activity by medium supplements (blood or serum). Purpuromycin or related compounds may have a potential role in the topical treatment of vaginitis and vaginosis.

100 Deals associated with MDL-63604

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Infections	Phase 3	US	Biosearch Italia SpA	-
Candidiasis, Vulvovaginal	Preclinical	US	Biosearch Italia SpA	-
Protozoan Infections	Preclinical	US	Biosearch Italia SpA	-